Develops a regional anticoagulant for hospital dialysis circuits and may develop an intravenous treatment for acute illnesses and ready-to-use syringe medicines for hospitals.
10-K for FY2025, filed Mar 23, 2026We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically…View ↗
Our portfolio is principally focused on our lead product candidate, Niyad (nafamostat mesylate), for use as a regional anticoagulant during…View ↗
We are developing Niyad to become the first and only FDA-approved regional anticoagulant for use in adult patients undergoing CRRT. Niyad…View ↗
$28K
10-K for FY2025, filed Mar 23, 2026
$28K ↗
Hospitals are a target market for ready-to-use syringe candidates, which they currently source mainly from compounding facilities or prepare in-house. Talphera is evaluating a potential Niyad launch using its own resources or a commercial partner.
10-K for FY2025, filed Mar 23, 2026
No. It lost $14.3M in FY2025.
Shrinking. Revenue fell 99% in 4 years, from $2.8M in FY2021 to $28K in FY2025, about 68% a year.
A narrower product focus
The older report described nafamostat and pre-filled syringe candidates and a planned DSUVIA divestment. The latest report says resources are focused on Niyad and the syringe candidates may be discontinued.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 23, 2026
Loading...